Swiss pharma company Idorsia announced that its novel dual endothelin receptor antagonist (ERA), Tryvio (aprocitentan), has ...

Macitentan tablets are an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension in adults to reduce the risks of disease progression and hospitalisation, ...

The updated recommendations now include TRYVIO™ (aprocitentan) – the first and only hypertension treatment targeting the ...

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Opsumit tablets, 10 mg, of ...

Investigators at St. John’s University have published preclinical data regarding their endothelin-1 receptor (ETRA) antagonist HJP-272 for the potential treatment of cancer.

Allschwil, Switzerland - August 12, 2025Idorsia Ltd (SIX: IDIA) announced today that The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, has nomina ...

An intravitreal implant shows promise in enhancing visual function and retinal structure in diabetic retinopathy patients, ...

LONG BEACH, Calif. -- Two different ocular implants eluting an endothelin antagonist showed early promise for slowing diabetic eye disease, according to two small studies reported here. In a ...

PER-001, delivered through a slow-release, dissolvable implant in the vitreous cavity of the eye, is designed to block endothelin signaling to increase ocular blood flow and prevent vision loss.

Endothelin B receptor inhibition increases axonal growth in vitro and ex vivo To investigate the role of ETBR signaling in axonal growth, we used different compounds to inihibit or activate endothelin ...